Evolocumab in Primary Prevention." 🧬🛡️🎯 LDL: Down 55%. CV Events: Down 25%.

🚀 VESALIUS-CV delivers powerful evidence: in high-risk patients without prior MI or stroke, evolocumab significantly reduced 3-point MACE by 25% and 4-point MACE by 19%, with LDL-C lowered to a median of 45 mg/dL.   💡 These results expand the horizon of prevention, showing that deep LDL reduction is both safe and effective in averting first cardiovascular events.   🫀 Strong science. Clear signal. A new chapter in preventive cardiology.   #Cardiology #LDL #Prevention #VESALIUSCV